Experts discuss anthracycline use in HER2+ breast cancer and provide insights into how patient scenarios, heterogeneity, and neuropathy concerns shape considerations in diverse clinical situations.
Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.
Experts discuss evidence-based strategies in neoadjuvant therapy for HER2+ breast cancer and provide insights on surgery-first considerations, disease size impact, and personalized pre-operative regimens.
Experts explore neoadjuvant HER2+ breast cancer care, delve into treatment goals, predictors, and personalized approaches, and uncover insights on chemotherapy, trastuzumab, and post-op considerations.